No profile data available.
Equillium, Inc. (EQ) is a healthcare company in the organ transfer treatment drugs industry, based in La Jolla, United States, with about 14 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$22.40 million. Its market capitalization was $89.41 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Equillium reported $0 in revenue for fiscal year 2025, down 100.0% from $41.10 million in fiscal year 2024.
$89.41 million as of October 9, 2026.
Listed companies of a similar size in the same industry (organ transfer treatment drugs) include Syndax Pharmaceuticals, Inc. (SNDX), Omeros Corporation (OMER), Eledon Pharmaceuticals, Inc. (ELDN), BioLineRx Ltd. (BLRX).